FYN and childhood gender nonconformity: As expected, PP2 and saracatinib, two different selective inhibitors of SFK (but not PP3, the negative control of PP2), significantly diminish the level of p-Fyn (Figure 2B), and of all p-Tyr proteins (Figure 2C), in both CGN types.